Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China.
Peripheral T-cell lymphoma (PTCL) is a set of rare and highly heterogeneous group of mature T- and NK-cell neoplasms associated with poor outcomes and lack of standard and effective therapies. The total number of newly diagnosed cases of PTCL yearly in China is estimated about 50,000. Chidamide (CS055) is a novel and orally active benzamide class of histone deacetylase (HDAC) inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, the enzymes that are involved and play an important role in tumor initiation and development in both tumor cells and their surrounding micro-environment. Functioning as a genuine epigenetic modulator, chidamide induces growth arrest and apoptosis in tumor cells and enhances cellular antitumor immunity. Based on the overall results from preclinical and phase I clinical studies, exploratory and pivotal phase II trials of chidamide for relapsed or refractory PTCL were conducted from March 2009 to May 2012, and the results led to CFDA approval of chidamide for the indication in December 2014, being the first approved orphan drug according to the research & development approach of orphan drugs in China, as well as the first orally active drug for PTCL in China and worldwide.
Chipscreen Biosciences Ltd, Shenzhen, China.
Xianping
X
Lu
Chipscreen Biosciences Ltd, Shenzhen, China.
Zhiqiang
Z
Ning
Chipscreen Biosciences Ltd, Shenzhen, China.
Zhibin
Z
Li
Chipscreen Biosciences Ltd, Shenzhen, China.
Haixiang
H
Cao
Chipscreen Biosciences Ltd, Shenzhen, China.
Xinhao
X
Wang
Chidamide; HDAC inhibitor; T-cell lymphoma; epigenetic; orphan drug
Mol Cancer Ther. 2008 Apr;7(4):759-68
18413790
J Clin Oncol. 2015 Aug 10;33(23):2492-9
26101246
Expert Opin Ther Targets. 2013 Jan;17(1):29-41
23062071
Biochem J. 2003 Mar 15;370(Pt 3):737-49
12429021
Ann Oncol. 2004 Oct;15(10):1447-9
15367401
Cancer Chemother Pharmacol. 2012 Jun;69(6):1413-22
22362161
Biomed Pharmacother. 2014 May;68(4):483-91
24721323
J Clin Oncol. 2012 Feb 20;30(6):631-6
22271479
J Clin Oncol. 2011 Mar 20;29(9):1182-9
21245435
J Clin Oncol. 2008 Sep 1;26(25):4124-30
18626005
Blood Rev. 2007 Jul;21(4):201-16
17512649
Ann Oncol. 2015 Aug;26(8):1766-71
26105599
Nat Rev Cancer. 2001 Dec;1(3):194-202
11902574
PLoS One. 2013 Aug 05;8(8):e70522
23940586
Am J Clin Pathol. 2012 Sep;138(3):429-34
22912361
Biochem J. 2012 May 1;443(3):735-46
22339555
Cancer Lett. 2009 May 8;277(1):8-21
18824292
Cancer Chemother Pharmacol. 2012 Apr;69(4):901-9
22080169
Blood. 1997 Jun 1;89(11):3909-18
9166827
Blood. 2014 Feb 27;123(9):1293-6
24345752
Cell. 2013 Mar 28;153(1):38-55
23540689